v1: 14 June 2022

Research Article

Severe Cutaneous Adverse Drugs Reactions: From Causes To Mechanisms

Peer-approved: 14 June 2022

© The Author(s) 2024. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 4 (2022)
ISSN: 2632-3834

Amelia Morgillo[1,2], Edoardo Marovino[3], Marcello Mazzarella[4], Valerio Barbagiovanni[4], Maria Francesca Randazzo[5]

1. University of Siena, Italy; 2. Department of Medicine and surgery, Saint Camillus International University of Health Sciences, Rome, Italy; 3. University of Milan, Italy; 4. Saint Camillus International University of Health Sciences, Rome, Italy; 5. University of Turin, Italy

Introduction: In the context of adverse drug reactions (ADR), skin manifestations are among one of the most frequent and often of such severity as to require access to the emergency room for emergency injection therapy. In this article we wanted to describe the characteristics of severe skin reactions both from a clinical point of view and with regard to the mechanisms and drugs most often involved in the cause.

Methods: Both the use of personal paper books and international website databases such as pubmed, scopus, google scholar, researchgate were used to develop the article, typing in keywords such as " skin ADR", "severe drug reactions", "lyell or steven-johnson syndrome"; associated with specific compound names. We have focused on recent articles and only related to severe ADRs.

Results and Conclusions: With regard to cutaneous ADRs, mild or moderate pictures can be distinguished such as morbilliform or scarlet eruptions with or without systemic symptoms, fortunately more frequent and generally treatable through the use of partially injected drugs and with oral therapy, which self-resolve in a few days. , up to severe and potentially fatal erythrodermal forms such as DRESS or steven-johnson and Lyell's syndromes, two different phases of the same process, with dermatological pictures similar to burns. Lists of higher-risk drugs have been established and every physician, including general practitioners, should know their potential for toxicity before prescribing and the need for closer clinical monitoring. Pay attention to the differential diagnosis with infectious processes, sometimes concomitant, and to primary forms of dermatosis such as severe forms of psoriasis or acne.

Corresponding author: Amelia Morgillo, dr.ameliamorgillo@gmail.com

Introduction

Drugs play an essential role in the treatment and prevention of many diseases and this is demonstrated by the enormous expansion of the pharmaceutical market from 2000 to today; however, no drug is free

 doi.org/10.32388/NZC06C

from side effects (sometimes even serious) and their use can be related to both the risk of ineffectiveness and poisoning from excessive doses. The definition of adverse drug reactions (ADR) has undergone changes in recent years.[1]

A first was developed, about thirty years ago, by the WHO which defined it as "*a response to a drug that is harmful and unintentional and that occurs at doses that are normally used in humans for the prophylaxis, diagnosis or therapy of a disease or that arises as a result of changes in the physiological state* "[2]. Today, the new legislation on pharmacovigilance has changed the definition of adverse reaction, now understood as "*any harmful and unwanted effect resulting from the use of a medicine*"[3][4]. The task of pharmacovigilance is to provide, on an ongoing basis, the best possible information on the safety of drugs, thus allowing appropriate measures to be taken and therefore ensuring that the drugs available on the market present, under the authorized conditions of use, a beneficial relationship. favorable risk for the population"[5][6]. In 2002 it was defined by the World Health Organization (WHO) as "the science and activities related to the identification, evaluation, understanding and prevention of adverse reactions or other drug-related problems".[7] The concept of ADR is part of the more general concept of "adverse event", defined as "any unwanted medical event, which arises in a patient (or in a subject included in a clinical study) who is administered a drug and who does not necessarily has a causal relationship with the treatment".[8] This definition, therefore, as can be understood, includes a wide variety of events that may arise during a drug therapy, such as adverse drug reactions, therapeutic failure and overdose. They are included in the ADR:

- Use not in accordance with the instructions contained in the marketing authorization (off-label)
- Medication errors, including accidental overdose
- Improper use
- Abuse of the drug
- Association to the exhibition for professional reasons

COLLATERAL EFFECT	any unintended effect of a drug arising at the doses normally used in humans and related to its pharmacological properties
ADVERSE EVENT	any unpleasant clinical phenomenon that occurs during a drug treatment but which does not necessarily have a causal relationship with the drug itself
ADVERSE DRUG REACTION (ADR)	response to a harmful and unintended drug that occurs at therapeutic doses. We speak of serious ADR if: - endangers the patient's life - requires or extends hospitalization - determines persistent or permanent disability - causes death

Table 1: definition in pharmacovigilance[9]

The causal relationship between the adverse event of the patient and the intake of the therapy is defined on the basis of clinical, pharmacological and also temporal criteria (in particular by evaluating, if possible, not only the dechallenge, or if the suspension of the treatment improves or heals the symptoms, but also the rechallenge, i.e. the re-exposure to increasing doses of the drug to evaluate the dose-response relationship). Most ADRs are dose-dependent and predictable, and above all not serious, and only about 20% are serious and unpredictable, mainly related to individual immunological (IgE or T lymphocytes mediated) or idiosyncratic mechanisms. In this article we will focus on severe ADRs and in particular on skin manifestations.[10][11]

Materials and Methods

An in-depth search was carried out starting from textbooks of pharmacology and pharmacovigilance both on paper and from the online platform "google books", supplemented by the subsequent addition of articles such as reviews and original articles working on databases such as scopus, Researchgate, Pubmed and Google Scholar, typing in keywords such as "skin ADR", "severe drug reactions", "lyell or steven-johnson syndrome"; associated with specific compound names. they have also been integrated with the authors' knowledge in the toxicological and pharmacological field.

Discussion

The skin is the most frequent target organ of ADRs, which represent 18-20% of the reports reported in the WHO database. Rashes and urticaria are the most frequent clinical patterns, usually of moderate severity, while rare (on the order of a few cases per million population) are ADRs associated with significant mortality and morbidity rates such as stevens syndrome. -johnson, di lyell ì, TEN (toxic epidermal necrolysis) and DRESS (drug rash with eosinophilia and systemic symptoms).[12] The clinical manifestations of cutaneous ADRs can derive both from the contact between the skin of a sensitized subject and the topical medicament (these are cases of allergic contact dermatitis or irritant contact dermatitis, with local reactions at the site of application and usually not serious) or by the development of more severe systemic hypersensitivity phenomena.[13] In these cases it is possible that the drug behaves as an allergen or hapten, according to the classical mechanisms of Gell and Coombs, or that it generates direct non-immunological activation of the complement, as well as possible idiosyncratic phenomena, from metabolic alterations, from interactions, etc.[14] The drugs most causing these phenomena are NSAIDs, antibiotics (especially beta-lactams), sulfonamides (eg:cotrimoxazole), anticonvulsants such as carbamazepine or lamotrigine, allopurinol and contrast agents, as well as anticancer and biological drugs.[15] In relation to the clinical pictures, the most frequent are certainly erythema, of various types and extent, accompanied

or not by subjective symptoms such as itching or burning. Depending on the type, they can be divided into morbilliform, roseoliform, scarlattiniform or pustular. They can also appear after 15-20 days from the suspension of the drug in question or within 24-48 hours from taking. They are generally not associated with systemic symptoms and resolve without success. Urticarial eruptions are also frequent, with itchy IgE-mediated wheals or mast cell release of preformed mediators (anaphylactoids, as in the case of opioids or muscle relaxants).[16][17]

The three images show three different severe cases of acute diffuse drug rashes

doi.org/10.32388/NZC06C



Image 1

doi.org/10.32388/NZC06C



Image 2



Image 3

There are also less common forms of drug eruptions such as lupus-like or psoriasiform ones, for example following the intake of lithium salts or interferon or beta blockers. In some cases it is actually an aggravation or a patenting of the underlying disease. [18] Diagnosis is generally not difficult given the acute onset and recent history of taking the causative drug therapy. However, the well-known case of skin exanthema arising after taking a beta lactam (usually amoxicillin or ampicillin) in patients with acute EBV infection (mononucleosis) or CMV (cytomegalovirus), two herpes viruses, deserves mention.[19][20] In some subjects, they can trigger an apparent drug rash following the administration of the aforementioned compounds even in the absence of true allergy. Various hypotheses have been made, probably they are idiosyncratic reactions or in any case from non-allergic phenomena given the absence of specific IgE or new rashes at the subsequent rechallenge with the drug after at least 6 months.[21] Some very severe clinical pictures of cutaneous ADRs will now be described, rare but potentially fatal if not managed adequately.[22]

- ***erythroderma:*** is defined as a rare inflammatory skin disease with erythema and generalized exfoliative dermatitisthat covers more than 80% of the body surface area and represents the maximum severity of various skin disorders[23]. In reality, the causes of such a clinical picture may be various; we will focus on the iatrogenic ones. Literature data show an index of 1-2 cases per 100,000 patients per year. The fundamental lesions are erythema, which involves all or almost all of the body surface, and scales of varying size, from fine or furfuraceous to lamellar. 14Other lesions may be present such as edema, skin thickening, discoloration or blistering. [24] Erythroderma involves a worsening of the patient's general condition and, apart from any itching or pain, there may be compromised water and electrolyte balance, reduced oncotic pressure with edema and altered mechanisms of body homeostasis. ADRs represent about 25% of erythroderma cases. Diagnosis of erythroderma is based on history and physical examination
- ***Rashes:*** Drug rashes, along with urticaria-angioedema, are the most common manifestations of cutaneous-mucosal ADRs. Rashes are extensive skin rashes consisting of repetitive lesions; based on the type of lesions they can be classified into maculo-papulosis, vesicular or hemorrhagic.[25] In general, in drug rashes, compared to infectious ones, the lesions are more numerous and of a more intense solore, they appear in patches, sometimes contain urticarial elements and therefore are associated with itching. In the pathogenesis we find as possible elements: a direct damage to the capillary wall (with consequent vasodilation, for example due to the local deposition of immune complexes) or a damage of skin cells, by direct or indirect action of the antigen at the epidermal or dermal level, being the lute with an important local immune system and vascular drainage.[26] The drugs most implicated in their pathogenesis are antibiotics, anticonvulsants, allopurinol, NSAIDs but have also been described for captopril, benzodiazepines, lithium, oral hypoglycemic agents, clonidine and phenothiazines. Viral infections such as HIV, CMV, or EBV are important co-factors in the induction of these reactions. They often appear within 2 weeks of dosing as light reddish or salmon red, point to multi-sized, confluent patches. They usually affect the trunk, neck, and upper extremities. Sometimes they can manifest as purpuric lesions in the sloping areas of the limbs. They tend to disappear 1-2 weeks after stopping the drug.
- ***stevens-johnson and lyell syndrome:*** they are clinically similar, except for their distribution. According to a commonly accepted definition, the changes affect <10% of the body surface in Stevens-Johnson syndrome and> 30% of the body surface in toxic epidermal necrolysis; the involvement between 10 and 30% of the body surface is considered an overlap between Stevens-Johnson syndrome and toxic epidermal necrolysis. The prevalence of these disorders is 1-5 people / million. The incidence and / or severity of both conditions are higher in bone marrow transplant recipients, Pneumocystis jirovecii infected HIV-positive patients, patients with systemic lupus erythematosus, and patients with other chronic rheumatic diseases. Drugs trigger more than 50% of Stevens-Johnson syndrome cases and up to 95% of toxic epidermal necrolysis cases[27]. The exact pathophysiological mechanism remains unknown:

however, altered drug metabolism (eg, inability to clear reactive metabolites) in some patients triggers a T-cell-mediated cytotoxic reaction to drug antigens, according to one hypothesis. present in keratinocytes. CD8 + T lymphocytes have been identified as important mediators of blister formation. The results suggest that granulisin released by cytotoxic T cells and natural killer cells may play a role in keratinocyte death; the concentration of granulisin in the bubble fluid correlates with the severity of the disease. Interleukin-15 has been shown to be increased in patients with Stevens-Johnson syndrome and toxic epidermal necrosis and has been shown to increase granulisin production. Another theory involves interactions between Fas (a membrane receptor that induces apoptosis) and its ligand, specifically a soluble form of the Fas ligand released by mononuclear cells, which leads to cell death and blistering. A genetic predisposition has also been suggested[28][29]. Within 1-3 weeks of initiating therapy with the responsible drug, patients experience general malaise, fever, headache, cough, and keratoconjunctivitis. The macules, which often take on a target-like appearance, then appear suddenly, usually on the face, neck and upper torso. In severe cases of toxic epidermal necrolysis syndrome, large layers of epithelium flake off throughout the body at pressure points (Nikolsky's sign), exposing exuding, painful, and erythematous skin. Painful scabs and oral erosions, keratoconjunctivitis, and genital disorders (eg, urethritis, phimosis, and vaginal synechiae) are present in up to 90% of cases[13]. The bronchial epithelium can also flake off, causing cough, dyspnoea, pneumonia, pulmonary edema, and hypoxemia.

Image 4 and 5: a case of stevens-johnson syndrome

doi.org/10.32388/NZC06C



Image 4

doi.org/10.32388/NZC06C

Image 5

Severe toxic epidermal necrolysis is similar to extensive burns; patients are acutely affected, may not be able to feed and open their eyes, and lose significant amounts of fluids and electrolytes. They are at high risk of infection, multiple organ failure and death. With early therapy, the survival rate approaches 90%. The score for assessing the severity of toxic epidermal necrolysis (Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) examines 7 factors within the first 24 h of admission to hospital of independent risk, to determine the mortality rate for a given patient[30].

SCORTEN: mortality risk assessment scale for SJ and NET

- age over 40
- skin detachment greater than 10%
- heart rate over 120
- plasma bicarbonates less than 20 nmol / l
- blood sugar over 14 nmol / l
- urea over 10 nmol / l

- ***Drug Rash with Eosinophilia and Systemic Symptoms (DRESS):*** It's a severe form of cutaneous ADR whose presentation includes systemic symptoms (fever, general malaise, pharyngitis and face edema), polyadenopathy, rash (of which various types of lesions have been described, urticarial, maculo-papular and sometimes purpuric , in over 50% of the body surface) and above all eosinophilia, often severe with at least one deep visceral affection (hepatitis, nephropathy, interstitial lung disease) but myocarditis, myositis and central neurological manifestations have also been described[15]. During DRESS, viral reactivation is frequently observed especially of EBV, CMV and HHV6 and 7. The histological examination of the skin shows lichenoid lymphocytic infiltrates predominantly of TCD8 + mononuclear mononuclear cells, or epidermotrope with cellular atypia that can evoke the diagnosis of pseudo-lymphoma[31]. Evolution can be fatal in 5-10% of cases and, even when benign, it can take months or up to a year for complete resolution[32]. In the literature, the drugs most frequently associated with this syndrome include antiepileptics (eg carbamazepine, lamotrigine and phenytoin) and allopurinol, as well as sulfonamides, minocycline and vancomycin. More recently, in May 2016, the Food and Drug Administration issued a warning highlighting that olanzapine could cause DRESS syndrome. CARM (New Zealand Center for Adverse Reaction Monitoring) received 39 reports of DRESS syndrome, between January 1, 2012 and December 31, 2016. The most frequently reported suspected drugs included allopurinol (13 cases), vancomycin (4 cases), piperacillin / tazobactam (3 cases) and sulfasalazine (3 cases).

In addition to these reactions described, it should also be remembered that several minor dermatological lesions have been described associated with a wide range of pharmacological therapies, both as a new onset and as a worsening of a pre-existing dermatosis. For example, acne lesions caused by anti-EGFR drugs or by steroids, psoriatic or lupus-like related to hydralazine or sulfonamides are known in the literature. The contribution of genetics has recently made it possible to clarify, for some cases, how there may be an individual predisposing susceptibility. For example, it has been shown that the presence of the HLA B1502 variant is associated, especially in people of Asian origin, with a severe skin hypersensitivity reaction to carbamazepine in 100% of cases or how the HLA B5701 variant is instead associated with hypersensitivity to abacavir and as this marker is indispensable in the development of this ADR such that it is necessary to carry out the genetic test before starting the therapy.

FOCUS ON: CUTANEOUS ADRS FROM MONOCLONAL ANTIBODIES

Among the adverse effects from monoclonal antibodies (mAb), the cutaneous ones are among the most frequent in terms of incidence, although fortunately in most cases they are not serious or in any case reversible effects.Various types of post-infusion skin reactions have been described, both acute (in terms of post-infusion rash) and after repeated or chronic exposure (and almost all types of elementary lesions have been associated with such ADRs, from urticarial ones lichenoid or lupus-like psoriatic ones) but the most common occur following the use of antitumor mAbs and in particular those used in immunotherapy[33]. By now, mAbs make up about 20% of drugs on the market and over 50% of those in pre-clinical development so it is not surprising that, given their wide use, these effects are also very frequent. For example, in the case of immune checkpoint inhibitory mAbs (anti-PDL1, anti-PD1 or anti-CTLA4) there are observed in more than one-third of the treated patients, mainly in the form of a maculopapular rash (eczema-like spongiotic dermatitis) and pruritus. A wide range of other dermatologic manifestations can also occur, including lichenoid reactions, psoriasis, acneiform rashes, vitiligo-like lesions, autoimmune skin diseases (e.g., bullous pemphigoid, dermatomyositis, alopecia areata), sarcoidosis or nail and oral mucosal changes. In addition, the use of anti-CTLA-4 and anti-PD-1 therapies in combination is associated with the development of more frequent, more severe and earlier cutaneous irAEs compared to single agents[34]. In most cases, these dysimmune dermatologic adverse events remain self-limiting and readily manageables.

Conclusions

Severe skin ADRs are generally rare or very rare reactions, but they can lead to high mortality rates if not diagnosed and managed quickly and in the best possible way. It is important to keep in mind that, although rare, there are patients at greater risk of developing them, such as those with a history of allergies, familiarity and, above all, exposed to particular categories of drugs such as antiepileptics or some antibiotics. It is also important for all healthcare professionals to adequately and promptly report these ADRs by filling in the paper forms from the AIFA website or through the free access portal "vigifarmaco" to keep the data updated on the real incidence of such cases.

Conflict of Interest Statement: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

A.M. and E.M. DECLARE: not to find themselves in situations of incompatibility or in conditions of conflict of interest also potential.

Funding Sources: A.M. and E.M did not receive any funding for this manuscript

Author Contributions: All authors read and approved the final version of the manuscript. We worked in an integrated way on the development of the article, contributing both to the drafting of all the paragraphs and to the complete bibliography and research on the site: E.M. came up with the idea of writing the article. E.M. initiated the work and helped to implement the search for sources and developed the theory and A.M. evaluated the sources used and implemented the pathophysiological aspects. Together, A.M. and E.M verified the methods, investigating the specific aspect and A.M. oversaw the results of this work. All authors discussed the results and contributed to the final manuscript.

References

1. ^*Drug Monitoring. The role of the hospital. WHO Tec hnical Report Series 425. World Health Organizatio n, Geneva, Switzerland, 1969.*
2. ^*Regolamento UE 1235/2010 entrato in vigore il 2 lu glio 2012.*
3. ^*Direttiva n. 2010/84/UE entrata in vigore 21 luglio 2012.*
4. ^*Muaed Jamal Alomar – Factor affecting the develo pment of adverse drug reactions*
5. ^*Amico Roxas M, Caputi A, Del Tacca M. Compendio di farmacologia generale e speciale 2 edizione. Edra, 2021.*
6. ^*Shear N.H, Dodiuk- Gad R.P. Advances in Diagnosis and Management of Cutaneous Adverse Drug Reacti on, current and Future Trends. Springer, 2018*
7. ^*Pippione M. Dermatologia e malattie sessualmente trasmesse 4 edizione. Minerva medica, 2019*
8. ^*Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):60.*

9. ^Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, et al. Incidence of Antibiotic-Related Rash in Childre n with Epstein-Barr Virus Infection and Evaluation of the Frequency of Confirmed Antibiotic Hypersensi tivity. Int Arch Allergy Immunol. 2018;176(1):33-38
10. ^Di Lernia V, Mansouri Y. Epstein-Barr virus and ski n manifestations in childhood. Int J Dermatol. 2013;5 2(10):1177-1184
11. ^Oakley AM, Krishnamurthy K. Stevens Johnson Syn drome. In: StatPearls. Treasure Island (FL): StatPearl s Publishing; April 19, 2021
12. ^Drug-induced Lyell and Stevens-Johnson syndrom es. Prescrire Int. 2009;18(99):20-22.
13. a, bLiotti L, Caimmi S, Bottau P, Bernardini R, et al. C linical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and t oxic epidermal necrolysis. Acta Biomed. 2019 Jan 29; 90(3-S):52-60
14. ^Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, S hear NH. Stevens-Johnson Syndrome and Toxic Epid ermal Necrolysis: An Update. Am J Clin Dermatol. 20 15 Dec;16(6):475-93.
15. a, bHusain Z, et al. DRESS syndrome: Part I. Clinical p erspectives. Journal of the American Academy of Der matology 2013; 68: 693 e1–14.
16. ^Bocquet H, et al. Drug-induced pseudolymphoma a nd drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semi nars in Cutaneous Medicine and Surgery 1996; 15: 25 0–7.
17. ^Husain Z, et al. DRESS syndrome: Part II. Managem ent and therapeutics. Journal of the American Acade my of Dermatology 2013; 68: 709 e1–9.
18. ^Kardaun SH, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multis ystem adverse drug reaction. Results from the prospe ctive RegiSCAR study. British Journal of Dermatolog y 2013; 169: 1071–80.
19. ^Myskowski PL, Halpern AC. Cutaneous adverse reac tions to therapeutic monoclonal antibodies for cance r. Curr Allergy Asthma Rep. 2008 Mar;8(1):63-8
20. ^Sibaud V. Dermatologic Reactions to Immune Chec kpoint Inhibitors : Skin Toxicities and Immunothera py. Am J Clin Dermatol. 2018 Jun;19(3):345-361
21. ^Collins LK, Chapman MS, Carter JB, Samie FH. Cuta neous adverse effects of the immune checkpoint inhi bitors. Curr Probl Cancer. 2017 Mar-Apr;41(2):125-1 28
22. ^Scavone C, Di Mauro C, Ruggiero R, Bernardi FF, Tr ama U, Aiezza ML, Rafaniello C, Capuano A. Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting S ystem in Southern Italy. Drugs Real World Outcomes. 2020 Mar;7(1):41-51. doi: 10.1007/s40801-019-001 74-7
23. ^Aihara M. Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol. 2011 Mar;38(3):246-54. doi: 10.1111/j.1346-8138.2010.01196.x. PMID: 213422 26.
24. ^Ramírez-González MD, Herrera-Enríquez M, Villa nueva-Rodríguez LG, Castell-Rodríguez AE. Role of epidermal dendritic cells in drug-induced cutaneous adverse reactions. Handb Exp Pharmacol. 2009;(18 8):137-62. doi: 10.1007/978-3-540-71029-5_7.
25. ^Shukla S, Rastogi S, Abdi SAH, Dhamija P, Kumar V, Kalaiselvan V, Medhi B. Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-s eizure medicines using VigiBase®. Seizure. 2021 Oc t;91:332-338. doi: 10.1016/j.seizure.2021.07.011.
26. ^Ahmed AF, Sukasem C, Sabbah MA, Musa NF, Moh amed Noor DA, Daud NAA. Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aro matic Antiepileptic-Induced Severe Cutaneous Adve rse Reactions. J Pers Med. 2021 May 7;11(5):383. doi: 10.3390/jpm11050383.
27. ^Strumia M, Perrin ML, Patras de Compaigno E, Con te C, Montastruc F, Lapeyre-Mestre M, Sibaud V, Des pas F. Dermatological adverse drug reactions of anti cancer drugs: International data of pharmacovigilan ce: VigiBase®. Therapie. 2022 Mar-Apr;77(2):219-2 27. doi: 10.1016/j.therap.2021.12.006.
28. ^Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull. 1987 D ec;34 Suppl 1:3-5. PMID: 2893692.
29. ^Isaacs M, Cardones AR, Rahnama-Moghadam S. D RESS syndrome: clinical myths and pearls. Cutis. 201 8 Nov;102(5):322-326.
30. ^Sharifzadeh S, Mohammadpour AH, Tavanaee A, E lyasi S. Antibacterial antibiotic-induced drug reactio n with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Eur J Clin Pharmacol. 2021 Mar;77(3):275-289. doi: 10.1007/s00228-020 -03005-9.
31. ^Miyagawa F, Asada H. Current Perspective Regardi ng the Immunopathogenesis of Drug-Induced Hyper sensitivity Syndrome/Drug Reaction with Eosinophil ia and Systemic Symptoms (DIHS/DRESS). Int J Mol Sci. 2021 Feb 21;22(4):2147. doi: 10.3390/ijms22042 147.
32. ^Doña I, Pérez-Sánchez N, Eguiluz-Gracia I, Muñoz -Cano R, Bartra J, Torres MJ, Cornejo-García JA. Pro gress in understanding hypersensitivity reactions to

nonsteroidal anti-inflammatory drugs. Allergy. 202 o Mar;75(3):561-575. doi: 10.1111/all.14032.

33. ^*Pretel M, Marquès L, España A. Drug-induced lupu s erythematosus. Actas Dermosifiliogr. 2014 Jan-Fe b;105(1):18-30. English, Spanish. doi: 10.1016/j.ad.2 012.09.007.*

34. ^*Oh JH, Yun J, Yang MS, Kim JH, Kim SH, Kim S, Cho i JH, Yim JJ, Kang HR. Reintroduction of Antitubercul ous Drugs in Patients with Antituberculous Drug-Re lated Drug Reaction with Eosinophilia and Systemic Symptoms. J Allergy Clin Immunol Pract. 2021 Sep;9 (9):3442-3449.e3. doi: 10.1016/j.jaip.2021.03.054.*

Declarations

Funding: The author(s) received no specific funding for this work.
Potential competing interests: The author(s) declared that no potential competing interests exist.